WELCOME!

The Stanford Cancer Institute’s (SCI) Comprehensive Cancer Research Training Program (CCRTP) is an annual immersive course that invites trainees to participate in a unique, comprehensive introduction to the vanguard of current cancer research.

This ambitious curriculum features daily plenary sessions on general topics followed by half-day sessions on two scientific themes, each featuring three to four presentations. Numerous nationally and internationally renowned Stanford faculty present didactic lectures and discussions on current topics of basic, translational and clinical cancer research.

Course Overview

The SCI has hosted its annual CCRTP course since September 2007. This educational initiative has been exceedingly well received.

The SCI invites high school, undergraduate, graduate, post-doctoral students (residents, clinical fellows, research fellows) and junior faculty members to attend CCRTP. In particular, trainees from the School of Medicine, School of Engineering and the School of Humanities and Sciences are encouraged to participate. The SCI will host this course Thursday, September 8 - Saturday, September 10 on Stanford campus.

This dynamic educational event features a plenary session on topic of general interest every morning followed by sessions on scientific themes with three presentations. The didactic lectures on current topics of basic, translational, clinical, and population science, are presented by nationally and internationally renowned faculty from Stanford University. Each didactic lecture is followed immediately by a discussion.
**SESSION I: PANCREAS CANCER**
Chair: James Ford, MD

**8:40 – 9:30 AM**
*Plenary Lecture*
Steven Artandi, MD, PhD
Stanford Cancer Institute Director

**9:30 – 10:10 AM**
*Deconstructing How Genotype and Cell of Origin Affect Pancreatic Cancer Evolution*
Laura Attardi, PhD
Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics

**10:10 – 10:30 AM: BREAK**

**10:30 – 11:10 AM**
*Immunologic Effects of Fibroblast Heterogeneity in Pancreatic Ductal Adenocarcinoma*
Daniel Delitto, MD, PhD
Assistant Professor of Surgery (General Surgery)

**11:10 – 11:50 AM**
*Mouse Models of Metastatic Cancer*
Monte Winslow, PhD
Associate Professor of Genetics and of Pathology

**SESSION II: DRUG DISCOVERY & DEVELOPMENT**
Chair: James Ford, MD

**12:50 – 1:40 PM**
*Plenary Lecture: Targeted Protein Degradation - A New Therapeutic Modality*
Nathanael Gray, PhD
Krishnan-Shah Family Professor of Chemical and Systems Biology

**1:40 – 2:30 PM**
*Next Generation Cancer Immune Therapies Targeting the Glycocalyx*
Carolyn Bertozzi, PhD
Anne T. and Robert M. Bass Professor of Chemistry

**2:20 – 2:40 PM: BREAK**

**2:40 – 3:20 PM**
*Early Phase Clinical Trials: Perpetual Hope and Concern*
Chris Chen, MD
Assistant Professor of Medicine (Oncology)

**3:20 – 4:00 PM:**
*Phenotypic Drug Discovery for Cancer Therapeutics*
Steven Corsello, MD
Assistant Professor of Medicine (Oncology)

**4:00 – 4:10 PM: CLOSING**
8:00 - 8:30 AM: BREAKFAST

8:30 - 8:40 AM: WELCOME
Melinda Telli, MD
Associate Professor of Medicine (Oncology)

SESSION I: CANCER DISPARITIES & POPULATION SCIENCES
Chair: Alyce Adams, PhD

8:40 – 9:30 AM
Plenary Lecture: Equity Effects of Real World Natural Experiments to Improve Access to Clinically Essential Treatments for Cancer Patients
Alyce Adams, PhD
Professor of Epidemiology and Population Health, and of Health Policy

9:30 – 10:10 AM
Adolescent Vaping: The What, Why and How to Prevent
Bonnie Halpern-Felsher, PhD
Professor of Pediatrics (Adolescent Medicine)

10:10 – 10:30 AM: BREAK

10:30 – 11:10 AM
Cancer Research Through the Lens of Health Equity
Lidia Schapira, MD
Professor Of Medicine (Oncology)

11:10 – 11:50 AM
Cancer Health Equity: The Cycle of Translational Research from Community to Bench to Community
Manali Patel, MD
Assistant Professor of Medicine (Oncology)

11:50 – 1:00 PM: LUNCH

SESSION II: HOW TO ...
Chair: James Ford, MD

1:00 – 1:40 PM
How to Speak Up Without Freaking Out
Matt Abrahams
Lecturer, Organizational Behavior Graduate School of Business

1:40 – 2:20 PM
How to Annoy, Bother, and Exasperate Your Statistician
Tara Maddala, PhD
Vice President of Clinical Development Delfi Diagnostics

2:20 – 2:40 PM: BREAK

2:40 – 3:20 PM
R01 Countdown: Tools for Writing Concise and Compelling Grants
Michaela Kiernan, PhD
Sr Research Scholar, Stanford Prevention Research Center

3:20 – 5:00 PM: POSTER SESSIONS & ICE CREAM SOCIAL
9:00 - 9:20 AM: BREAKFAST

9:20 - 9:30 AM: WELCOME
Laura Attardi, PhD
Catharine and Howard Avery Professor of the School of Medicine and of Genetics

SESSION I: Immunotherapies
Chair: Melinda Telli, MD

9:30 – 10:10 AM
Successful Translational Research Measures PK, PD and Clinical Outcomes: CAR-FACS
David Miklos, MD, PhD
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

10:10 – 10:50 AM
Coopting the TCR Machinery to Enhance CAR T Cell Efficacy and Specificity
Robbie Majzner, MD
Assistant Professor of Pediatrics (Hematology/Oncology)

10:50 – 11:30 AM
Manipulating Myeloid Cells for the Treatment of Cancer
Edgar Engleman, MD
Professor of Pathology and Medicine (Immunology and Rheumatology)

11:30 – 11:40 AM: BREAK

11:40 – 12:05 PM
How to Find Your First Biotech Job
Mark Lee, MD, PhD
Former SVP and Global Head for Personalized Healthcare, Genentech

12:05 – 12:30 PM
Canary Crest Program
Sharon Pitteri, PhD
Associate Professor (Research) Of Radiology (Cancer Early Detection Canary Center)

11:40 – 12:05 PM
Cancer Biology Program PhD Experience
Matthew Pech, PhD
Director, Discovery Biology at TenSixteen Bio

12:05 – 12:30 PM
Postdoc Experience
Patrick Neuhoefer, PhD
Instructor, Stanford Cancer Institute

11:40 – 12:05 PM
Junior Faculty Session
David Kurtz, MD, PhD
Assistant Professor of Medicine (Oncology)

12:05 – 12:30 PM
Junior Faculty Session
Erinn Rankin, PhD
Assistant Professor of Radiation Oncology and of Obstetrics and Gynecology

12:30 PM: CLOSING & CERTIFICATES
Laura Attardi
Program Director

Dr. Laura D. Attardi received her B.A. in Biochemistry from Cornell University and her Ph.D. in Molecular and Cellular Biology from the University of California at Berkeley, where she worked with Professor Robert Tjian. Professor Attardi did her postdoctoral training with Professor Tyler Jacks at the MIT Center for Cancer Research. In 2000, she joined the Departments of Radiation Oncology and Genetics at the Stanford University School of Medicine, and she was promoted to Professor in 2014. The overarching goal of her research program is to better define the mechanisms by which the p53 transcription factor and tumor suppressor promotes different responses in different settings, ranging from beneficial tumor suppressive responses to pathological effects such as phenotypes characteristic of developmental disorders. Toward this end, her laboratory has sought to deconstruct p53 pathways in vivo in an integrative approach leveraging mouse genetics, cell biology, genomics, and biochemistry techniques. She focuses in particular on two common and deadly cancers, pancreatic ductal adenocarcinoma and lung adenocarcinoma. Understanding the beneficial and deleterious effects of p53 action is ultimately critical for developing the best strategies to target p53 in cancer and in pathological contexts. Professor Attardi has been a recipient of a Damon Runyon Scholar Award, an American Cancer Society Research Scholar Grant, and a Leukemia and Lymphoma Society Scholar Award. She was named an AAAS fellow in 2007 and an NIH/NCI Outstanding Investigator in 2015. Professor Attardi also serves as a co-director of the Stanford University Cancer Biology Ph.D. program, a co-program leader of the Cancer Biology and Cancer Stem Cell program in the Stanford Cancer Institute, a member of the Basic Sciences Advisory Group to Dean Lloyd Minor, and a co-director of the Stanford University Pancreas Cancer Research Group. She will be co-Editor in chief of the Annual Reviews of Cancer Biology beginning in 2022.

Jim Ford
Program Director

Dr. Jim Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention in families and populations. Dr. Ford graduated in 1984 from Yale University where he later received his M.D. degree from the School of Medicine.
in 1989. He was an internal medicine resident and oncology fellow at Stanford, and joined the faculty in 1998. He is currently Professor of Medicine (Oncology) and Genetics, Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford Medicine.

Dr. Ford's clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes for prevention and early diagnosis of cancer in high-risk individuals and populations. He is also Director of Stanford’s Cancer Genomics Program, performing next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies, directs the Stanford Molecular Tumor Board, and is a PI on numerous trials of genomically targeted therapies, including the national Combo-MATCH trial.

Dr. Ford is devoted to the training and mentoring of future scientists and physician-investigators. He is the Associate Director for Training and Education for the Stanford Cancer Institute, and a founding advisor for the Stanford Master’s Program in Genetic Counseling. He is also a current and former editor of numerous scientific journals, including *Cancer Research*, *DNA Repair*, and *PLoS Genetics*, and he is the founding Editor-in-Chief of *JCO Precision Oncology*.

Melinda Telli
Program Director

Dr. Melinda Telli, Associate Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, is the Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women’s Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of ‘beyond BRCA’ DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.

Dr. Telli received her undergraduate degree from the University of Pennsylvania Magna Cum Laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at
Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and currently serves as a Komen Scholar, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015 and 2018), Triple Negative Breast Cancer Foundation Hero Award (2018), and Susan G. Komen SF Bay Area Visionary Award (2019). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.